4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.

The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.

Argus Session date unavailable

+0.93% session move Open Argus

Details

News Market Reaction – FDMT

The recorded move for FDMT in the trading session of this news was +0.93%.

Data tracked by StockTitan Argus. Session date unavailable.

Key Figures

RSU grant size: 23,600 RSUs New employees: 4 employees Inducement plan year: 2025 plan +1 more

RSU grant size

23,600 RSUs

Granted to four new non-executive employees on January 13, 2026

New employees

4 employees

Recipients of inducement RSU awards

Inducement plan year

2025 plan

2025 Employment Inducement Award Plan used for the grants

Nasdaq rule

Rule 5635(c)(4)

Authority cited for inducement equity grants under Nasdaq Global Market rules

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Corporate update

   24h Move

   +8.1%

   Outlined late-stage retinal milestones and cash runway through H2 2028.

2. Dec 17

   Clinical data update

   24h Move

   -20.1%

   Reported positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis.

3. Dec 12

   Inducement equity grants

   24h Move

   +1.0%

   Granted 13,800 RSUs to new non-executive employees under inducement plan.

4. Dec 08

   Conference participation

   24h Move

   +3.5%

   Announced presentation at the 44th Annual J.P. Morgan Healthcare Conference.

5. Nov 20

   Conference participation

   24h Move

   -4.3%

   Planned fireside chat and meetings at Evercore Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units (rsus), employment inducement award plan, nasdaq global market

3 terms

restricted stock units (rsus) financial

"granted four new non-executive employees 23,600 Restricted Stock Units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

employment inducement award plan financial

"The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan"

An employment inducement award plan is a company program that grants stock, stock options, or other equity-based incentives to recruit or retain a specific new employee, similar to offering a signing bonus but paid in company shares. Investors watch these plans because they can dilute existing ownership, change management incentives, and increase compensation expense, all of which can affect share value and future company performance.

nasdaq global market regulatory

"Rule 5635(c)(4) of The Nasdaq Global Market for equity grants"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company’s board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did 4D Molecular Therapeutics (FDMT) grant on January 13, 2026?

The company granted 23,600 RSUs to four new non-executive employees.

Under which plan were the FDMT inducement RSUs granted?

The RSUs were granted under the 2025 Employment Inducement Award Plan approved by the board in February 2025.

Why did FDMT use Nasdaq Rule 5635(c)(4) for the January 2026 grants?

Nasdaq Rule 5635(c)(4) allows equity awards to induce new employees to enter employment, which the company used for these grants.

Were the FDMT RSU grants for executive or non-executive employees?

The grants were for four new non-executive employees.

Does the January 2026 RSU announcement from FDMT include financial guidance or earnings figures?

No; the announcement only discloses the RSU grants and the governing inducement plan, not earnings or guidance.

When did 4D Molecular Therapeutics publicly announce the RSU grants for FDMT?

The company announced the grants on January 17, 2026, noting the awards were made on January 13, 2026.